Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com
Ripretinib Demonstrates Clinical Benefit in KIT Exon 11, 17/18–Mutated Advanced GIST
January 24th 2023Second-line ripretinib produced a clinical benefit in patients with advanced gastrointestinal stromal tumor harboring KIT exon 11 and 17/18 mutations who progressed on or were intolerant to imatinib.
Read More
FDA Receives Premarket Approval Application for Noninvasive CRC Screening Test
January 24th 2023Geneoscopy has submitted a premarket approval application to the FDA for a noninvasive, stool-based, at-home screening test to detect colorectal cancer and advanced adenomas in average-risk individuals.
Read More
Frontline NALIRIFOX Elicits OS Benefit in Metastatic Pancreatic Ductal Adenocarcinoma
January 21st 2023First-line treatment with the combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin produced a clinically meaningful and statistically significant improvement in overall survival and progression-free survival vs nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma, according to results from the phase 3 NAPOLI 3 trial.
Read More
FDA Approves Tucatinib Plus Trastuzumab for RAS Wild-type, HER2+ Metastatic Colorectal Cancer
January 19th 2023The FDA has granted accelerated approval to tucatinib in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Read More
UK’s MHRA Approves Zanubrutinib for CLL and MZL
January 19th 2023The Medicines and Healthcare Products Regulatory Agency has approved zanubrutinib in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia and the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20–based therapy.
Read More
Adjuvant Atezolizumab/Bevacizumab Combo Meets RFS End Point in Early-Stage HCC
January 19th 2023Adjuvant treatment with the combination of atezolizumab and bevacizumab demonstrated a statistically significant improvement in recurrence-free survival compared with active surveillance in patients with early-stage hepatocellular carcinoma at high risk of disease recurrence.
Read More
Perioperative Toripalimab Plus Chemotherapy Meets EFS End Point in NSCLC
January 18th 2023Perioperative treatment with the combination of toripalimab plus platinum-containing doublet chemotherapy, followed by toripalimab monotherapy as consolidation therapy after surgery, significantly extended event-free survival compared with chemotherapy plus placebo in patients with operable NSCLC.
Read More
TP-3654 Showcases Early Signs of Tolerability, Clinical Activity in Myelofibrosis
January 17th 2023The PIM1 kinase inhibitor TP-3654 was well tolerated and showcased preliminary signs of activity, including spleen volume reduction, symptom improvement, and broad cytokine reduction, in patients with myelofibrosis who were previously treated with or were ineligible for a JAK inhibitor.
Read More
BXCL701 Plus Pembrolizumab Generates Promising Responses in Small Cell Neuroendocrine mCRPC
January 11th 2023The combination of BXCL701 and pembrolizumab produced encouraging responses in patients with small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer, according to topline data from a phase 2 trial.
Read More
FDA Grants Fast Track Designation to CFI-402257 for ER+/HER2– Breast Cancer
January 11th 2023The FDA has granted a fast track designation to best-in-class threonine tyrosine kinase inhibitor CFI-402257 for the treatment of adult patients with estrogen receptor (ER)–positive/HER2-negative advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy.
Read More
At-Home Screening Test Demonstrates Sensitivity, Specificity in Detecting CRC
January 10th 2023Geneoscopy’s at-home, stool-based diagnostic screening test to detect colorectal cancer and advanced adenomas in average-risk individuals displayed high sensitivity and specificity, meeting the primary objectives of the phase 3 CRC-PREVENT trial.
Read More
IBI351 Gets Breakthrough Therapy Designation for KRAS G12C–Mutated NSCLC in China
January 10th 2023The Center for Drug Evaluation of China's National Medical Products Administration has granted a breakthrough therapy designation to IBI351 for the treatment of patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation who have received at least 1 prior line of systemic therapy.
Read More
Adding the CDK4/6 inhibitor trilaciclib to platinum-based chemotherapy and avelumab maintenance produced an overall response rate comparable to chemotherapy and maintenance avelumab alone in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
Read More
Tumor treating fields plus standard-of-care therapies led to a statistically significant and clinically meaningful improvement in overall survival vs SOC alone in patients with stage IV NSCLC who progressed while on or after platinum chemotherapy, meeting the primary end point of the LUNAR trial.
Read More
Japan Approves Second-line Axi-cel for LBCL
December 23rd 2022Japan’s Ministry of Health, Labor and Welfare has approved axicabtagene ciloleucel for the initial treatment of patients with relapsed/refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma.
Read More
Frontline Domvanalimab Plus Zimberelimab Improves Responses in PD-L1–High Metastatic NSCLC
December 22nd 2022The combination of domvanalimab plus zimberelimab with or without etrumadenant generated an improvement in overall response rate and progression-free survival compared with zimberelimab alone in patients with PD-L1–high metastatic non–small cell lung cancer, according to findings from the phase 2 ARC-7 trial.
Read More
European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC
December 21st 2022The European Commission has approved the combination of olaparib plus abiraterone acetate and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.
Read More
FDA Expands Approval of Pemetrexed Injection for Metastatic NSCLC Without EGFR/ALK Aberrations
December 20th 2022The FDA has approved an additional indication for pemetrexed by injection, an alternative to standard pemetrexed, in combination with pembrolizumab and platinum-based chemotherapy for the initial treatment of patients with metastatic, nonsquamous non–small cell lung cancer without EGFR or ALK genomic tumor aberrations.
Read More